Last reviewed · How we verify
GLPG1690 film-coated tablets
At a glance
| Generic name | GLPG1690 film-coated tablets |
|---|---|
| Sponsor | Galapagos NV |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care (PHASE3)
- A Clinical Study to Test How Effective and Safe GLPG1690 is for Subjects With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care (PHASE3)
- A Clinical Study to Test Long Term Safety of GLPG1690 for Patients With Systemic Sclerosis (PHASE2)
- A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Systemic Sclerosis (PHASE2)
- A Study in Healthy Male Volunteers to Look at How the Test Medicine GLPG1690 is Taken up by the Body When Given by Mouth and Into a Vein as an Injection (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |